Table 3.
Risk factor | ORa | 95% CL | AORb | 95% CL | ARRc | 95% CLd | |||
---|---|---|---|---|---|---|---|---|---|
Home follow-upe |
3.27 |
2.62 |
4.09 |
2.94 |
2.33 |
3.71 |
1.21 |
1.18 |
1.24 |
9 months of isoniazid |
1.50 |
1.29 |
1.74 |
0.88 |
0.73 |
1.05 |
0.97 |
0.92 |
1.01 |
Female |
1.04 |
0.89 |
1.21 |
|
|
|
|
|
|
Age categories: |
|
|
|
|
|
|
|
|
|
Age<6 |
6.80 |
4.11 |
11.25 |
5.40 |
3.19 |
9.13 |
1.07 |
1.06 |
1.08 |
Age 6 to <18 |
2.71 |
2.23 |
3.30 |
2.64 |
2.10 |
3.32 |
1.11 |
1.09 |
1.12 |
Age 18 to <35 |
ref |
|
|
ref |
|
|
ref |
|
|
Age 35 and older |
1.21 |
1.00 |
1.45 |
1.18 |
0.96 |
1.44 |
1.05 |
0.99 |
1.10 |
Patient referral reason: |
|
|
|
|
|
|
|
|
|
Correctional/rehabilitation |
0.23 |
0.18 |
0.31 |
0.43 |
0.32 |
0.57 |
0.59 |
0.47 |
0.71 |
TST converters/TB contactsf |
1.30 |
0.99 |
1.70 |
1.23 |
0.93 |
1.63 |
1.04 |
0.98 |
1.10 |
Postpartum women |
0.44 |
0.33 |
0.59 |
0.64 |
0.47 |
0.87 |
0.80 |
0.67 |
0.94 |
TST+g from screening |
ref |
|
|
ref |
|
|
ref |
|
|
Place of birth: |
|
|
|
|
|
|
|
|
|
Africa |
1.34 |
0.72 |
2.50 |
1.29 |
0.67 |
2.49 |
1.07 |
0.87 |
1.21 |
Asia |
1.60 |
1.21 |
2.13 |
1.62 |
1.18 |
2.22 |
1.09 |
1.03 |
1.14 |
Europe |
1.83 |
1.03 |
3.25 |
1.93 |
1.06 |
3.53 |
1.10 |
1.01 |
1.16 |
Latin America |
1.17 |
0.91 |
1.52 |
1.25 |
0.93 |
1.67 |
1.06 |
0.98 |
1.13 |
Unknown |
0.95 |
0.62 |
1.45 |
1.06 |
0.67 |
1.68 |
1.02 |
0.87 |
1.14 |
USA | ref | ref | ref |
aAnalysis by logistic regression.
bAdjusted OR. Multivariate model included: type of follow-up, regimen, age (categories), patient referral reason, and place of birth.
cAdjusted Risk Ratio, calculated from adjusted OR.
dAdjusted Risk Ratio 95% confidence limits, calculated from adjusted OR.
eHome-based follow-up with public health nurses and community health workers.
fTuberculin skin test converters or contacts of cases with active tuberculosis.
gTST+: Tuberculin skin test positive.